Ph IIA Study (SOC +/- NS5B)

Inclusion Criteria:

- Subjects chronically infected with HCV genotype 1 as documented by: positive for
anti-HCV antibody, HCV RNA, or a positive HCV genotype test at least 6 months prior
to Screening, and positive for HCV RNA and anti-HCV antibody at Screening

- HCV RNA ≥ 10*5* IU/mL at Screening

- Less than 4 weeks total prior therapy with an IFN formulation (ie, IFNα, pegIFNα-2a),
or RBV and no exposure to IFN or RBV within 24 weeks of Randomization

- Results of a biopsy obtained ≤ 24 months prior to Randomization showing no evidence
of cirrhosis

- Body Mass Index (BMI) of 18 to 35 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²
at Screening

Exclusion Criteria:

- Liver transplant recipients

- Documented or suspected HCC by imaging or liver biopsy

- Evidence of a medical condition associated with chronic liver disease other than HCV
(such as but not limited to: hemochromatosis, autoimmune hepatitis, metabolic liver
disease, alcoholic liver disease, toxin exposures)

- History of chronic hepatitis B virus (HBV) as documented by HBV serologies (eg.
HBsAg-seropositive). Patients with resolved HBV infection may participate (eg.
HBsAb-seropositive)

- Current or known history of cancer (except in situ carcinoma of the cervix or
adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
to enrollment